187 related articles for article (PubMed ID: 38520790)
21. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
23. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
[TBL] [Abstract][Full Text] [Related]
24. Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment.
Mpekris F; Panagi M; Michael C; Voutouri C; Tsuchiya M; Wagatsuma C; Kinoh H; Osada A; Akinaga S; Yoshida S; Martin JD; Stylianopoulos T
J Control Release; 2023 Jan; 353():956-964. PubMed ID: 36516902
[TBL] [Abstract][Full Text] [Related]
25. Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy.
Zhu H; Liu Q; Miao L; Musetti S; Huo M; Huang L
Nanoscale; 2020 Feb; 12(5):3400-3410. PubMed ID: 31989142
[TBL] [Abstract][Full Text] [Related]
26. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
27. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
28. Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Li Q; Qin S; Tian H; Liu R; Qiao L; Liu S; Li B; Yang M; Shi J; Nice EC; Li J; Lang T; Huang C
Small; 2023 Jun; 19(23):e2207201. PubMed ID: 36899444
[TBL] [Abstract][Full Text] [Related]
29. Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment.
Wu S; Huang H; Sun R; Gao DS; Ye F; Huang J; Li E; Ni A; Lu KG; Chen K; Jiang J; Morel PA; Zhong Z; Lu B
Cancer Res Commun; 2023 Aug; 3(8):1460-1472. PubMed ID: 37546701
[TBL] [Abstract][Full Text] [Related]
30. Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy.
Su L; Pan W; Li X; Zhou X; Ma X; Min Y
Acta Biomater; 2023 Mar; 158():698-707. PubMed ID: 36563773
[TBL] [Abstract][Full Text] [Related]
31. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
33. Normalizing tumor microenvironment with nanomedicine and metronomic therapy to improve immunotherapy.
Mpekris F; Voutouri C; Panagi M; Baish JW; Jain RK; Stylianopoulos T
J Control Release; 2022 May; 345():190-199. PubMed ID: 35271911
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
[TBL] [Abstract][Full Text] [Related]
35. Sonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translation.
Snipstad S; Sulheim E; de Lange Davies C; Moonen C; Storm G; Kiessling F; Schmid R; Lammers T
Expert Opin Drug Deliv; 2018 Dec; 15(12):1249-1261. PubMed ID: 30415585
[TBL] [Abstract][Full Text] [Related]
36. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy.
Zheng X; Kuai J; Shen G
Immunotherapy; 2023 Apr; 15(6):429-442. PubMed ID: 36880262
[TBL] [Abstract][Full Text] [Related]
37. Stabilizing tumor resident mast cells restores T cell infiltration and sensitizes sarcomas to PD-L1 inhibition.
Panagi M; Mpekris F; Voutouri C; Hadjigeorgiou AG; Symeonidou C; Porfyriou E; Michael C; Stylianou A; Martin JD; Cabral H; Constantinidou A; Stylianopoulos T
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38578281
[TBL] [Abstract][Full Text] [Related]
38. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
Front Immunol; 2022; 13():965492. PubMed ID: 36389685
[TBL] [Abstract][Full Text] [Related]
39. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
40. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
